Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Deals

July 21 Quick Takes: Turnstone’s $80M round to advance oncolytic virus, TIL programs

Plus: Vedanta, bluebird, Cytokinetics and more

July 22, 2021 12:58 AM UTC

Six months after Turnstone Biologics Corp. acquired Myst Therapeutics Inc. to gain tumor-infiltrating lymphocyte technologies that complement its existing pipeline of oncolytic viruses, the biotech has raised $80 million in a series D round led by PFM Health Sciences and Point72. Also participating are Eventide Asset Management, Citadel-backed Surveyor Capital, Ridgeback Capital Investments, Takeda Ventures Inc., CaaS Capital, JM Family Enterprises Inc., Northleaf Capital Partners and 404 Bio, as well as prior investors Versant Ventures, OrbiMed, F-Prime Capital, Sectoral Asset Management, Sixty Degree Capital, Brace Pharma Capital and Teralys Capital.

Microbiome company Vedanta Biosciences Inc. has completed a $68 million series D round as it prepares to advance lead candidate VE303 into a Phase III trial to treat Clostridioides difficile infection, due to begin in mid-2022. The round includes a $25 million contribution from Pfizer Inc. (NYSE:PFE) that was announced in January. Vedanta also expects to start a Phase II study this half of another therapy, VE202, to treat ulcerative colitis. Magnetar Capital led the new round alongside Verition Fund Management, Fosun Health Capital, co-founder PureTech Health plc (LSE:PRTC; NASDAQ:PRTC), Rock Springs Capital, Skyviews Life Science, JSR Corp., SymBiosis, Shumway Capital, and Seventure Partners’ Health for Life Capital...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article